Actelion Pharmaceuticals has gained the rights to develop and commercialise Auxilium Pharmaceuticals’ Xiaflex® (collagenase clostridium histolyticum), a first-in-class biologic for Dupuytren’s contracture (DC) and Peyronie’s disease (PD), in Canada, Australia, Brazil and Mexico in a deal worth up to US$68.5 M. The drug has already received regulatory approval in the US and Europe for DC and has been accepted for review for this indication in Canada. Auxilium will continue to assume primary responsibility for the drug’s ongoing Phase III development programme for PD, data from which are expected late in the second half of 2012.